MNP和MVP方案治疗晚期非小细胞肺癌的临床疗效观察  

A comparison of the therapeutic effects of MNP and MVP regimen for treatment of advanced non small cell lung cancer

作　　者：芮立新[1] 彭万仁[1] 

机构地区：[1]安徽医科大学第一附属医院肿瘤科

出　　处：《癌症》1998年第3期207-208,共2页Chinese Journal of Cancer

摘　　要：目的：比较异长春花碱（ＮＶＢ）与丝裂霉素（ＭＭＣ）和顺铂（ＰＤＤ）组成的ＭＮＰ方案及长春花碱酰胺（ＶＤＳ）与ＭＭＣ和ＰＤＤ组成的ＭＶＰ方案治疗非小细胞肺癌的疗效。方法：６９例晚期非小细胞肺癌随机分成两组，其中ＭＮＰ组３４例，ＭＶＰ组３５例。结果：显示ＭＮＰ组有效率为５８．８％，而ＭＶＰ组为５１．４％，两组间疗效无显著性差异（Ｐ＞０．０５）。ＭＮＰ组的骨髓抑制较ＭＶＰ组明显（Ｐ＜０．０１），而胃肠道反应及神经毒性两组均无显著性差异（Ｐ＞０．０５）。结论：表明ＭＮＰ和ＭＶＰ可以做为非小细胞肺癌的一线治疗方案。Objective: To evaluate the curative effects of MNP (MMC+NVB+PDD) regimen and MVP (MMC+VDS+PDD) regimen on non-small cell lung cancer. Methods: 69 cases of advanced non-small cell lung cancer were randomly divided into two groups, of whom 34 cases were treated with MNP regimen, 35 cases with MVP regimen. Result: The result showed that respose rates of MNP regimen and MVP regimen were 58.8% and 51.4%, respectively. There was no statistical significant difference between them (P>0.05). Myelosuppression of MNP regimen was more serious than MVP regimen (P<0.01). However, both gastrointestinal tract reaction and neurotoxicity had no stastical difference between two regimens (P>0.05). Conclusion: It is concluded that both MNP regimgn and MVP regimen can be used as first-line regimens for treatment of non-small cell lung cancer.

关 键 词：非小细胞肺癌 药物疗法 肺肿瘤 MNP MVP 

分 类 号：R734.205[医药卫生—肿瘤] R730.53[医药卫生—临床医学]